News

Scottish GPs lose out in overall DES fund allocation

10-Mar-06

Scottish practices will be eligible for only half the money available to English practices under new directed enhanced services (DESs), according to medical secretary of Argyll and Clyde LMC Dr John Ip.

There will be £12.6 million of new money, which works out at roughly £12,000 per practice as opposed to £24,700 in England, excluding the access DES.

Four new DESs on cardiovascular risk data, carers, learning disability and cancer referrals are close to agreement in Scotland.

Dr Ip was pleased that these DESs would reward patient-focused services in contrast to England, where new DESs cover choice, commissioning and IT.

The DESs in Wales will also put patients first, according to Dr Andrew Dearden, chairman of GPC Wales, and agreement is imminent in Northern Ireland.

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Healthcare Republic Forums

 

Registrar

A question of capacity

Medicolegal advisor, Dr John Holden addresses some dilemmas on consent that may be faced by GPs. Read more

Workplace-based assessment

The WPBA should be seen as a developmental process, says the RCGP's Dr Jane Mamelok. Read more

Professional development - The role of an educational supervisor

Working as an educational supervisor can be stimulating and rewarding, says Dr Alexander Williams. Read more

Show all articles

 

Latest Clinical Articles

Primary hyperparathyroidism

Contributed by Mr David Scott-Coombes, consultant endocrine surgeon at the University Hospital of Wa... Read more

Clinical Review - Headache in children

Contributed by Dr David Kernick, a GPSI in headache, based in Exeter. Read more

Carpal tunnel syndrome

Section 1: Epidemiology and aetiology Read more

Show all clinical articles

MIMS Product News

Toviaz

New drug - Toviaz

Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bla... Read more

New drug - Tasigna

Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome po... Read more

Ciproxin licensed for UTI in children

The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line tr... Read more

Jobs

 

Job of the Week